Analyst Price Targets — RGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 6, 2026 12:47 pm | — | Evercore ISI | $160.00 | $139.37 | TheFly | Repligen price target raised to $160 from $150 at Evercore ISI |
| May 14, 2026 8:19 pm | Dan Leonard | RBC Capital | $160.00 | $103.38 | TheFly | Repligen resumed with an Outperform at RBC Capital |
| May 5, 2026 7:44 pm | Matthew Stanton | Jefferies | $142.00 | $125.61 | TheFly | Repligen price target lowered to $142 from $152 at Jefferies |
| April 20, 2026 1:03 pm | — | Canaccord Genuity | $145.00 | $132.19 | TheFly | Repligen price target lowered to $145 from $165 at Canaccord |
| April 17, 2026 8:48 am | — | Redburn Partners | $160.00 | $127.09 | TheFly | Repligen initiated with a Buy at Rothschild & Co Redburn |
| April 14, 2026 10:43 am | Luke Sergott | Barclays | $145.00 | $122.59 | TheFly | Repligen price target lowered to $145 from $175 at Barclays |
| January 16, 2026 12:18 pm | Dan Leonard | UBS | $200.00 | $161.69 | TheFly | Repligen price target raised to $200 from $190 at UBS |
| December 15, 2025 11:29 am | — | Wells Fargo | $190.00 | $157.33 | TheFly | Repligen price target raised to $190 from $175 at Wells Fargo |
| December 15, 2025 10:56 am | — | Barclays | $200.00 | $157.33 | TheFly | Repligen price target raised to $200 from $175 at Barclays |
| October 29, 2025 10:58 am | — | Canaccord Genuity | $165.00 | $151.57 | TheFly | Repligen price target raised to $165 from $150 at Canaccord |
Latest News for RGEN
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
American Capital Management Inc. acquired a new position in shares of Repligen Corporation (NASDAQ: RGEN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 361,055 shares of the biotechnology company's stock, valued at approximately $49,262,000. Repligen comprises
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
WALTHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. Olivier Loeillot, President and Chief Executive Officer and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RGEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.